TY - JOUR
TI - Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma
AU - Chantzi, N.I.
AU - Tiniakos, D.G.
AU - Palaiologou, M.
AU - Goutas, N.
AU - Filippidis, T.
AU - Vassilaros, S.D.
AU - Dhimolea, E.
AU - Mitsiou, D.J.
AU - Alexis, M.N.
JO - Journal of Cancer Research and Clinical Oncology
PY - 2013
VL - 139
TODO - 9
SP - 1489-1498
PB - 
SN - 0171-5216, 1432-1335
TODO - 10.1007/s00432-013-1467-4
TODO - estrogen receptor beta;  estrogen receptor beta 1;  estrogen receptor beta 2;  unclassified drug, adult;  aged;  article;  breast carcinoma;  cancer prognosis;  cancer recurrence;  cell nucleus;  clinical feature;  correlation analysis;  cytoplasm;  disease course;  disease free survival;  estrogen receptor alpha negative breast carcinoma;  female;  follow up;  histopathology;  human;  human cell;  human tissue;  immunohistochemistry;  lymph node metastasis;  major clinical study;  multivariate analysis;  postmenopause;  priority journal;  proportional hazards model;  protein expression;  protein function;  triple negative breast cancer;  univariate analysis, Adult;  Aged;  Breast Neoplasms;  Cell Nucleus;  Cytoplasm;  Estrogen Receptor alpha;  Estrogen Receptor beta;  Female;  Follow-Up Studies;  Humans;  Immunoenzyme Techniques;  Lymph Nodes;  Middle Aged;  Neoplasm Grading;  Neoplasm Recurrence, Local;  Prognosis;  Survival Rate;  Tumor Markers, Biological;  Young Adult
TODO - Purpose: Our aim was to examine the prognostic significance of ERbeta1 and ERbeta2 expression in ERalpha-negative breast carcinomas. Materials and methods: We evaluated nuclear and cytoplasmic expression of ERbeta1 and ERbeta2 by immunohistochemistry in a group of 95 patients with long follow-up. ERbeta1 and ERbeta2 status was correlated with clinicopathological parameters and disease outcome. Univariate and multivariate analyses of ERbeta1 and ERbeta2 as independent markers of disease-free survival (DFS) were carried out using the Cox proportional hazards model. Results: Nuclear ERbeta1 (nERbeta1) and nERbeta2 status was positively correlated (p = 0.01). nERbeta1 positivity was associated with low histological grade (p = 0.01) in all patients and in the nERbeta2-positive subgroup (p = 0.03) but not in the nERbeta2-negative (p = 0.27). nERbeta2 positivity was associated with lymph node involvement and tumor relapse in all cases (p < 0.00 and p < 0.00, respectively) and in the nERbeta1-negative subgroup (p < 0.00 and p < 0.00, respectively) but not in the nERbeta1-positive (p = 0.09 and p = 0.20, respectively). nERbeta2 positivity was associated with poor DFS in all patients (log-rank p <0.00), in the post-menopausal patient subgroup (log-rank p = 0.02) and in the HER2-negative (triple-negative) subgroup (log-rank p = 0.04). Cox multivariate analysis including ERbeta1, ERbeta2 and established clinicopathological variables highlighted ERbeta2 as an independent marker of early disease recurrence (hazard ratio 4.87; 95 % confidence interval 1.07-22.3; p = 0.04). Conclusion: High nERbeta2 is an independent marker of early relapse in ERalpha-negative breast carcinoma, and in particular, in the nERbeta1-negative, the post-menopausal patient and the triple-negative subgroups. These findings suggest that inhibition of expression and/or function of ERbeta2 could improve disease outcome. © 2013 Springer-Verlag Berlin Heidelberg.
ER -